Tao Shi-Cong, Yuan Ting, Zhang Yue-Lei, Yin Wen-Jing, Guo Shang-Chun, Zhang Chang-Qing
Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, China.
Institute of Microsurgery on Extremities, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, China.
Theranostics. 2017 Jan 1;7(1):180-195. doi: 10.7150/thno.17133. eCollection 2017.
Osteoarthritis (OA) is the most common joint disease throughout the world. Exosomes derived from miR-140-5p-overexpressing synovial mesenchymal stem cells (SMSC-140s) may be effective in treating OA. We hypothesized that exosomes derived from SMSC-140 (SMSC-140-Exos) would enhance the proliferation and migration abilities of articular chondrocytes (ACs) without harming extracellular matrix (ECM) secretion.
SMSCs were transfected with or without miR-140-5p. Exosomes derived from SMSCs or SMSC-140s (SMSC-Exos or SMSC-140-Exos) were isolated and identified. Proliferation, migration and ECM secretion were measured in vitro and compared between groups. The mechanism involving alternative Wnt signalling and activation of Yes-associated protein (YAP) was investigated using lentivirus, oligonucleotides or chemical drugs. The preventative effect of exosomes in vivo was measured using Safranin-O and Fast green staining and immunohistochemical staining.
Wnt5a and Wnt5b carried by exosomes activated YAP via the alternative Wnt signalling pathway and enhanced proliferation and migration of chondrocytes with the side-effect of significantly decreasing ECM secretion. Highly-expressed miR-140-5p blocked this side-effect via RalA. SMSC-140-Exos enhanced the proliferation and migration of ACs without damaging ECM secretion in vitro, while in vivo, SMSC-140-Exos successfully prevented OA in a rat model.
These findings highlight the promising potential of SMSC-140-Exos in preventing OA. We first found a potential source of exosomes and studied their merits and shortcomings. Based on our understanding of the molecular mechanism, we overcame the shortcomings by modifying the exosomes. Such exosomes derived from modified cells hold potential as future therapeutic strategies.
骨关节炎(OA)是全球最常见的关节疾病。源自过表达miR-140-5p的滑膜间充质干细胞(SMSC-140s)的外泌体可能对治疗OA有效。我们推测源自SMSC-140的外泌体(SMSC-140-Exos)将增强关节软骨细胞(ACs)的增殖和迁移能力,同时不损害细胞外基质(ECM)分泌。
用或不用miR-140-5p转染滑膜间充质干细胞。分离并鉴定源自滑膜间充质干细胞或SMSC-140s的外泌体(SMSC-Exos或SMSC-140-Exos)。体外测量增殖、迁移和ECM分泌,并在组间进行比较。使用慢病毒、寡核苷酸或化学药物研究涉及非经典Wnt信号传导和Yes相关蛋白(YAP)激活的机制。使用番红O和固绿染色以及免疫组织化学染色测量外泌体在体内的预防作用。
外泌体携带的Wnt5a和Wnt5b通过非经典Wnt信号通路激活YAP,增强软骨细胞的增殖和迁移,但有显著降低ECM分泌的副作用。高表达的miR-140-5p通过RalA阻断了这种副作用。SMSC-140-Exos在体外增强了ACs的增殖和迁移,同时不损害ECM分泌,而在体内,SMSC-140-Exos在大鼠模型中成功预防了OA。
这些发现突出了SMSC-140-Exos在预防OA方面的潜在前景。我们首次发现了外泌体的潜在来源,并研究了它们的优缺点。基于我们对分子机制的理解,我们通过修饰外泌体克服了缺点。这种源自修饰细胞的外泌体作为未来的治疗策略具有潜力。